Targeted protein degradation is becoming explored as a substitute method in cancer, whereby the all-natural protein degradation procedure is co-opted for therapeutic uses. Not too long ago designed novel molecules named proteolysis-concentrating on chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. One ligand